Douglas E. Giordano Net Worth

The estimated Net Worth of Douglas E. Giordano is at least 56.7 千$ dollars as of 6 February 2013. Douglas Giordano owns over 5,000 units of Viatris stock worth over 56,700$ and over the last 12 years Douglas sold VTRS stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Douglas Giordano VTRS stock SEC Form 4 insiders trading

Douglas has made over 1 trades of the Viatris stock since 2013, according to the Form 4 filled with the SEC. Most recently Douglas bought 5,000 units of VTRS stock worth 130,000$ on 6 February 2013.

The largest trade Douglas's ever made was buying 5,000 units of Viatris stock on 6 February 2013 worth over 130,000$. On average, Douglas trades about 2,500 units every 0 days since 2013. As of 6 February 2013 Douglas still owns at least 5,000 units of Viatris stock.

You can see the complete history of Douglas Giordano stock trades at the bottom of the page.

What's Douglas Giordano's mailing address?

Douglas's mailing address filed with the SEC is C/O PFIZER INC., 235 EAST 42ND STREET, NEW YORK, NY, 10017.

Insiders trading at Viatris

Over the last 4 years, insiders at Viatris have traded over 17,988,707$ worth of Viatris stock and bought 85,788 units worth 1,086,462$ . The most active insiders traders include Ian C Read、James M Kilts、Robert J Coury. On average, Viatris executives and independent directors trade stock every 13 days with the average trade being worth of 708,761$. The most recent stock trade was executed by Rajiv Malik on 28 August 2024, trading 100,000 units of VTRS stock currently worth 1,195,000$.

What does Viatris do?

Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.

Complete history of Douglas Giordano stock trades at Zoetis Inc、Viatris

Viatris executives and stock owners

Viatris executives and other stock owners filed with the SEC include:

• Robert J. Coury,
  Exec. Chairman
• Rajiv Malik,
  Pres & Exec. Director
• Anthony Mauro,
  Pres of Developed Markets
• Michael Goettler,
  CEO & Exec. Director
• Sanjeev Narula,
  Chief Financial Officer
• Klimentiy Vakhrameev,
  Director
• Aleksey Sapronov,
  Director
• Anton Checha,
  Director
• Ivan Myasoedov,
  Chief Accountant
• Mikhail Churkin,
  General Director (CEO), Director
• Marina Filippenko,
  Chairman of the Board
• Melissa Trombetta,
  Head of Global Investor Relations
• David Bayles,
  Chief Compliance Officer
• Brian S. Roman,
  Global Gen. Counsel
• Ramkumar Rayapureddy,
  Chief Information Officer
• Paul B. Campbell,
  Chief Accounting Officer, Sr. VP & Corp. Controller
• Sanjeev Kumar Sethi,
  Chief Operating Officer
• Richard A Mark,
  
• Goff Corinne Le,
  Chief Commercial Officer
• Coelho Rogerio Vivaldi,
  
• Elisha W Finney,
  
• James M Kilts,
  
• Brian Roman,
  Chief Legal Officer
• Leo Frans Groothuis,
  
• Rajiv Malik,
  
• Bryan Supran,
  Director
• Douglas E. Giordano,
  Director
• Dillon Jo Ellen Lyons,
  
• Margaret M. Madden,
  Director
• Inc Pfizer,
  10% owner
• Neil F Dimick,
  Director
• Melina E Higgins,
  
• Xiangyang (Sean) Ni,
  President, Greater China
• Sanjeev Narula,
  Chief Financial Officer
• Robert J Coury,
  Executive Chairman
• Ian C Read,
  Director
• Der Meer Mohr Pauline Van,
  Director
• Paul Campbell,
  See Remarks
• Menassie Taddese,
  See Remarks
• Harry Korman,
  
• Michael Goettler,
  Chief Executive Officer
• Scott Andrew Smith,
  Chief Executive Officer
• Andrew Cuneo,
  See Remarks
• Theodora Mistras,
  Chief Financial Officer
• Mark W Parrish,
  
• Anthony Mauro,
  See Remarks
• W Don Cornwell,